Special guest semianr with Dr. Asaf ZviranDate:
Lecture / Seminar
Title: Ultra-sensitive detection and monitoring of solid cancers using whole-genome mutation integration
Location: Arthur and Rochelle Belfer Building for Biomedical Research
Lecturer: Dr. Asaf Zviran
Organizer: Azrieli Institute for Systems Biology
Details: Co-Founder, CEO&CSO, C2i Genomics
Abstract: Early detection of recurrence and monitoring of Molecular Residual Disease (MRD) ... Read more Early detection of recurrence and monitoring of Molecular Residual Disease (MRD) post-surgery is critical for clinical decision-making to tailor personalized treatments across solid cancers. C2i Genomics has developed an ultra-sensitive whole-genome ctDNA test, allowing extremely accurate and sensitive monitoring of patients with solid tumors. Here we present results from applying whole-genome sequencing (WGS) and identification of ctDNA across a variety of adult and pediatric solid tumors. We integrate a genome-wide mutation and copy number monitoring approach coupled with advanced signal processing and Artificial Intelligence (AI) for measuring the tumor load from low-input blood samples (~1mL of plasma) with ultra-sensitive detection. The increased sensitivity allowed clinical detection of tumor fraction down to 5*10-5 and recurrence detection sensitivity achieving >65% at the first two months after definitive treatment, enabling earlier clinical intervention for high-risk patients.